At a glance
- Originator Carlbiotech
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 11 Apr 1996 Discontinued-II for Glaucoma in Denmark (Ophthalmic)
- 11 Apr 1996 Discontinued-II for Glaucoma in Germany (Ophthalmic)
- 11 Apr 1996 Discontinued-II for Glaucoma in USA (Ophthalmic)